Search

Your search keyword '"Cournoyer S"' showing total 45 results

Search Constraints

Start Over You searched for: Author "Cournoyer S" Remove constraint Author: "Cournoyer S"
45 results on '"Cournoyer S"'

Search Results

1. Renal Recovery for Patients with ANCA-Associated Vasculitis and Low eGFR in the ADVOCATE Trial of Avacopan

2. A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function

3. Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial

4. Renal Recovery for Patients with ANCA-Associated Vasculitis and Low eGFR in the ADVOCATE Trial of Avacopan

5. Renal Recovery for Patients with ANCA-Associated Vasculitis and Low eGFR in the ADVOCATE Trial of Avacopan

6. Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease: Results From the CREDENCE Trial and Meta-Analysis

7. Effect of SGLT2 inhibitors on stroke and atrial fibrillation in diabetic kidney disease: Results from the CREDENCE trial and meta-analysis

8. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

9. Avacopan for the Treatment of ANCA-Associated Vasculitis

10. Abstracts

11. Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups

12. The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics

13. Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups Results From the Randomized CREDENCE Trial

14. Effect of Cinacalcet on Cardiovascular Disease in Patients Undergoing Dialysis

15. Cinacalcet, fibroblast growth factor-23, and cardiovascular disease in hemodialysis: The evaluation of cinacalcet HCl therapy to lower cardiovascular events (EVOLVE) trial

16. Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease

18. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease

19. Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes

20. Study of Heart and Renal Protection (SHARP): Randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease.

22. Mineral and bone disease - CKD 1-5

23. Mineral and bone disease - CKD 5D

29. Superdeformed band up to spin $\sim$ (127/2 in $^{149}$Gd)

30. Superdeformed band up to spin ∼(127/2 in ^{149}Gd

32. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

33. The effects of cinacalcet in older and younger patients on hemodialysis: The evaluation of cinacalcet HCL therapy to lower cardiovascular events (EVOLVE) trial

34. Safety and Efficacy of Paclitaxel-Eluting Balloon Angioplasty for Dysfunctional Hemodialysis Access: A randomized trial Comparing with Angioplasty Alone.

35. GX15-070 (Obatoclax), a Bcl-2 family proteins inhibitor engenders apoptosis and pro-survival autophagy and increases Chemosensitivity in neuroblastoma.

36. An Adjustable Dalteparin Sodium Dose Regimen for the Prevention of Clotting in the Extracorporeal Circuit in Hemodialysis: A Clinical Trial of Safety and Efficacy (the PARROT Study).

37. Expression of Disialoganglioside (GD2) in Neuroblastic Tumors: A Prognostic Value for Patients Treated With Anti-GD2 Immunotherapy.

38. Autophagy is associated with chemoresistance in neuroblastoma.

39. Expression of CD133 in differentiated thyroid cancer of young patients.

40. Diagnostic utility of molecular and cytogenetic analysis in lipoblastoma: a study of two cases and review of the literature.

41. Genotype analysis of tumor-initiating cells expressing CD133 in neuroblastoma.

42. A long femur scan field does not alter proximal femur bone mineral density measurements by dual-energy X-ray absorptiometry.

43. Antecedent 99mTc-MDP and 99mTc-sestamibi administration corrupts bone mineral density measured by DXA.

45. Superdeformed band up to spin ~(127/2 in 149Gd.

Catalog

Books, media, physical & digital resources